About retinoblastoma
Cancer occurs when normal cells transform to evade the regular cell cycle process. Retinoblastoma is a rare eye cancer. It occurs in children of age less than 15 years; the disease is common in children younger than five years, especially children less than two years. The disease affects the retina and is caused by a mutation in the gene RB1. It usually appears in one eye and gradually spreads to the other. Clinically, retinoblastoma is classified into two: unilateral retinoblastoma, tumor in one eye, and bilateral retinoblastoma, tumor in both the eyes.
Technavio's analysts forecast the global retinoblastoma market to grow at a CAGR of 3.57% over the period 2014-2019.
Covered in this report
The report includes the present scenario and the growth prospects of the global retinoblastoma market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of retinoblastoma.
Technavio's report, Global Retinoblastoma Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as the market segmentation. The report includes a discussion of the key vendors operating in this market.
Key regions
• Americas
• APAC
• EMEA
Key vendors
• Baxter
• Bristol-Myers Squibb
• GlaxoSmithKline
• Spectrum Pharmaceuticals
Other prominent vendors
• BioLineRx
• Cellceutix
• Icon Bioscience
• Neotropix
• RXi Pharmaceuticals
• Recombio
Key market driver
• Increasing public awareness
• For a full, detailed list, view our report
Key market challenge
• Treatment abandonment
• For a full, detailed list, view our report
Key market trend
• Localized treatment approach
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Understanding the Disease
06.2 Etiology
06.3 Classification
06.3.1 Bilateral Retinoblastoma
06.3.2 Unilateral Retinoblastoma
06.4 Symptoms
06.5 Diagnosis
06.5.1 Patient Examination
06.5.2 Imaging Tests
06.5.3 Biopsy Tests
06.5.4 Clinical Tests
06.6 Epidemiology
06.7 Staging
06.7.1 Intraocular Staging
06.7.2 Extraocular staging
06.8 Management
06.8.1 Cryotherapy
06.8.2 Chemotherapy
06.8.3 Photocoagulation
06.8.4 Radiation therapy
06.8.5 Surgery
06.8.6 Thermo therapy
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Pipeline Analysis
08.1 Key Information of the Pipeline Candidates
08.1.1 NTX-010
08.1.2 Racotumomab
08.1.3 Kevetrin
08.1.4 BL-8040
08.1.5 Melphalan
08.1.6 RNAi Oligonucleotide for Retinoblastoma
09. Market Segmentation by Therapeutic Class of Drugs
09.1 Alkylating Agents
09.2 Antimetabolites
09.3 Microtubule Inhibitors
09.4 Cytotoxic Antibiotics
09.5 Topoisomerase Inhibitors
09.6 Others
10. Market Segmentation by Disease Status
11. Geographical Segmentation
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 Baxter
19.2.2 Bristol-Myers Squibb
19.2.3 GlaxoSmithKline
19.2.4 Spectrum Pharmaceuticals
19.3 Other Prominent Vendors
20. Key Vendor Analysis
20.1 Baxter International Inc.
20.1.1 Key Facts
20.1.2 Business Description
20.1.3 Business Segmentation
20.1.4 Business Strategy
20.1.5 Revenue by Business Segmentation
20.1.6 Revenue by Geographical Segmentation
20.1.7 Key Developments
20.1.8 SWOT Analysis
20.2 Bristol-Myers Squibb
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Key Product Offerings
20.2.4 Revenue by Geography
20.2.5 Business Strategy
20.2.6 Key Information
20.2.7 SWOT Analysis
20.3 GlaxoSmithKline
20.3.1 Business Overview
20.3.2 Business Segmentation
20.3.3 Business Segmentation by Revenue 2012 and 2013
20.3.4 Sales by Geography
20.3.5 Key Facts
20.3.6 Pipeline Products
20.3.7 Business Strategy
20.3.8 Key Information
20.3.9 SWOT Analysis
List of Exhibits:
Exhibit 1: Market Research Methodology
Exhibit 2: Classification of Retinoblastoma
Exhibit 3: Symptoms: Percentage Occurrence in Patients
Exhibit 4: Techniques Used for Diagnosing Retinoblastoma
Exhibit 5: Intraocular Staging
Exhibit 6: Extraocular Staging
Exhibit 7: Retinoblastoma: Treatment Options
Exhibit 8: Global Retinoblastoma Market 2014-2019 (US$ million)
Exhibit 9: Pipeline Portfolio
Exhibit 10: Global Retinoblastoma Market by Therapeutic Class of Drugs
Exhibit 11: Global Retinoblastoma Market by Disease Status
Exhibit 12: Global Retinoblastoma Market: Percentage Share of Cases (2014)
Exhibit 13: Global Retinoblastoma Market by Geographical Segmentation 2014
Exhibit 14: Baxter
Exhibit 15: Bristol Myers-Squibb
Exhibit 16: GlaxoSmithKline
Exhibit 17: Spectrum Pharmaceuticals
Exhibit 18: Baxter International Inc. : Business Segmentation
Exhibit 19: Baxter International Inc.: Revenue by Business Segmentation 2013
Exhibit 20: Baxter International Inc.: Revenue by Geographical Segmentation 2013
Exhibit 21: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
Exhibit 22: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
Exhibit 23: GlaxoSmithKline: Business Segmentation 2013
Exhibit 24: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 25: GlaxoSmithKline: Sales by Geography 2013
Exhibit 26: GlaxoSmithKline: Pipeline Products 2013
